{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:49:56Z","timestamp":1789145396276,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Daratumumab is a human IgG\u03ba monoclonal antibody targeting CD38 with direct on-tumor and immunomodulatory mechanisms of action. Daratumumab-based treatment is a standard of care for multiple myeloma (MM) based on data from randomized controlled trials. Real-world studies, such as that presented here from China, provide important data to complement randomized trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This ongoing observational study describes real-world treatment patterns and outcomes among patients with symptomatic, newly diagnosed or relapsed\/refractory MM treated with daratumumab in China. Patients must have received\u2009\u2264\u20093 prior lines of MM therapy. Data were collected prospectively and\/or retrospectively, depending on time of treatment initiation. The primary study objective was to describe treatment patterns and clinical outcomes, and the secondary objective was to assess the safety and tolerability of daratumumab treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>As of the cutoff date (April 30, 2023) for this analysis, 212 patients had received\u2009\u2265\u20091 dose of daratumumab at 13 sites in China. Regimens included daratumumab monotherapy (<jats:italic>n<\/jats:italic>\u2009=\u200922) and daratumumab combined with dexamethasone only (<jats:italic>n<\/jats:italic>\u2009=\u200921), proteasome inhibitors (PIs)\u2009\u00b1\u2009dexamethasone (<jats:italic>n<\/jats:italic>\u2009=\u200957), immunomodulatory drugs (IMiDs)\u2009\u00b1\u2009dexamethasone (<jats:italic>n<\/jats:italic>\u2009=\u200972), PIs and IMiDs\u2009\u00b1\u2009dexamethasone (<jats:italic>n<\/jats:italic>\u2009=\u200929), and other combinations (<jats:italic>n<\/jats:italic>\u2009=\u200911). Daratumumab was initiated by 16.5%, 53.3%, 16.5%, and 13.7% of patients across the first, second, third, and fourth lines of therapy, respectively. A best overall response of partial response or better was achieved by 71.8% of evaluable patients and very good partial response or better was achieved by 51.4% of patients. Estimated 6-month and 12-month progression-free survival rates were 84.3% and 75.0%, respectively. Outcomes were generally more favorable with daratumumab-based combinations than with daratumumab monotherapy. Serious treatment-emergent adverse events were reported in 13.7% of patients, with pneumonia (4.7%) the only serious event in\u2009\u2265\u20095 patients. The most frequently reported adverse drug reactions were leukopenia (6.6%), neutropenia (5.7%), and thrombocytopenia (5.7%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This observational study provides real-world insights into treatment decisions for Chinese patients with MM. The effectiveness and safety results support the use of daratumumab-based treatment as a standard-of-care therapy in Chinese patients with newly diagnosed or relapsed\/refractory MM. This study is ongoing, with continued collection of outcomes data during a longer follow-up.\n<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13925-3","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T06:23:34Z","timestamp":1746599014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed\/refractory multiple myeloma"],"prefix":"10.1186","volume":"25","author":[{"given":"Luqun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canchan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"3","key":"13925_CR1","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840\u20138.","journal-title":"J Immunol"},{"issue":"21","key":"13925_CR2","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","volume":"124","author":"J Lammerts van Bueren","year":"2014","unstructured":"Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, Voorhorst M, Gresnigt E, Wiegman L, Buijsse O, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474.","journal-title":"Blood"},{"issue":"2","key":"13925_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311\u201321.","journal-title":"MAbs"},{"issue":"3","key":"13925_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcgamma receptor-mediated cross-linking. J Immunol. 2016;197(3):807\u201313.","journal-title":"J Immunol"},{"issue":"3","key":"13925_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NWCJ, Weiss BM, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384\u201394.","journal-title":"Blood"},{"issue":"3","key":"13925_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cyto.a.23693","volume":"95","author":"HC Adams III","year":"2019","unstructured":"Adams HC III, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, et al. High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A. 2019;95(3):279\u201389.","journal-title":"Cytometry A"},{"key":"13925_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","volume":"35","author":"T Casneuf","year":"2021","unstructured":"Casneuf T, Adams HC III, van de Donk NWCJ, Abraham Y, Bald J, Vanhoof G, Van der Borght K, Smets T, Foulk B, Nielsen KC, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2021;35:573\u201384.","journal-title":"Leukemia"},{"issue":"14","key":"13925_CR8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319\u201331.","journal-title":"N Engl J Med"},{"issue":"8","key":"13925_CR9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366.","journal-title":"N Engl J Med"},{"issue":"10245","key":"13925_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos M-V, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186\u201397.","journal-title":"The Lancet"},{"issue":"6","key":"13925_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328.","journal-title":"N Engl J Med"},{"issue":"10192","key":"13925_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Bene MC, Broijl A, Caillon H, Caillot D, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29\u201338.","journal-title":"Lancet"},{"issue":"4","key":"13925_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"11","key":"13925_CR14","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"9","key":"13925_CR15","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/j.clml.2021.04.012","volume":"21","author":"J Lu","year":"2021","unstructured":"Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: phase 3 LEPUS (MMY3009) study. Clin Lymphoma Myeloma Leuk. 2021;21(9):e699\u2013709.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"13925_CR16","unstructured":"Jing H, Yang L, Qiu L, Jiang B, Fu C, Li J, Yang M, Qi M, Fan N, Ji J, et al. Clinical efficacy of daratumumab monotherapy in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter phase 1 study. Presented at the CSH National Hematology Academic Conference; September 24\u201327, 2020; Hangzhou, China."},{"issue":"6","key":"13925_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, et al. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study. Clin Lymphoma Myeloma Leuk. 2023;23(6):446-455 e444.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"13925_CR18","doi-asserted-by":"publisher","first-page":"12487","DOI":"10.1182\/blood-2022-163763","volume":"140","author":"VTM Hungria","year":"2022","unstructured":"Hungria VTM, Trufelli D, Saes J, Nakajima K, Leonel L, Gaiolla R, Galvez K, Remaggi G, Bittencourt R, Maiolino A, et al. Demographic and clinical characteristics of multiple myeloma patients in Latin America. Blood. 2022;140(suppl 1):12487\u20139.","journal-title":"Blood"},{"issue":"1","key":"13925_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/10428194.2023.2273746","volume":"65","author":"A Saunders","year":"2024","unstructured":"Saunders A, Slaff S, Subbiah K, Gu T, Ang KK, Quan MA, Rosenberg AS. Clinical characteristics, treatment patterns, and outcomes among African American and White patients with multiple myeloma in the United States. Leuk Lymphoma. 2024;65(1):109\u201317.","journal-title":"Leuk Lymphoma"},{"issue":"31","key":"13925_CR20","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.2217\/fon-2023-0021","volume":"19","author":"J Martinez-Lopez","year":"2023","unstructured":"Martinez-Lopez J, Bailey A, Lambert A, Luke E, Ribbands A, Erler-Yates N, Valluri S, Haefliger B, Gay F. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncol. 2023;19(31):2103\u201321.","journal-title":"Future Oncol"},{"issue":"7","key":"13925_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, et al. Clinical profiles of multiple myeloma in Asia\u2014an Asian Myeloma Network study. Am J Hematol. 2014;89(7):751\u20136.","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"13925_CR22","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1182\/blood-2021-147523","volume":"138","author":"J Richter","year":"2021","unstructured":"Richter J, Singh E, Rice MS. Real-world multiple myeloma treatment patterns by patient characteristics and outcomes in the United States. Blood. 2021;138(suppl 1):4114.","journal-title":"Blood"},{"issue":"3","key":"13925_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/ejh.14032","volume":"111","author":"S Hentzen","year":"2023","unstructured":"Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, Rubinstein S, Mohyuddin GR. Attrition and withdrawal in multiple myeloma randomized controlled trials: a systematic review. Eur J Haematol. 2023;111(3):491\u20138.","journal-title":"Eur J Haematol"},{"issue":"4","key":"13925_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1182\/blood-2017-10-809293","volume":"131","author":"M Gavriatopoulou","year":"2018","unstructured":"Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M, Ziogas DC, Kanellias N, Terpos E, Dimopoulos MA. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018;131(4):464\u20137.","journal-title":"Blood"},{"issue":"1","key":"13925_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1186\/s12885-021-08881-7","volume":"21","author":"S Atrash","year":"2021","unstructured":"Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, Lafeuille MH, Lefebvre P, Rossi A. Treatment patterns and effectiveness of patients with multiple myeloma initiating daratumumab across different lines of therapy: a real-world chart review study. BMC Cancer. 2021;21(1):1207.","journal-title":"BMC Cancer"},{"issue":"4","key":"13925_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4274\/tjh.galenos.2023.2023.0029","volume":"40","author":"A Tekinalp","year":"2023","unstructured":"Tekinalp A, Geduk A, Akdeniz A, Terzi Demirsoy E, Gursoy V, Aslaner Ak M, Bagci M, Secilmis S, Keklik Karadag F, Oruc Uysal A, et al. Experience of daratumumab in relapsed\/refractory multiple myeloma: a multicenter study from Turkiye. Turk J Haematol. 2023;40(4):242\u201350.","journal-title":"Turk J Haematol"},{"issue":"1","key":"13925_CR27","first-page":"25","volume":"37","author":"A Dang","year":"2023","unstructured":"Dang A. Real-world evidence: a primer. Pharmaceut Med. 2023;37(1):25\u201336.","journal-title":"Pharmaceut Med"},{"issue":"1","key":"13925_CR28","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.clml.2022.10.007","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: updated snalysis of LEPUS. Clin Lymphoma Myeloma Leuk. 2023;23(1):e51\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"13925_CR29","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","volume":"72","author":"Z Liu","year":"2023","unstructured":"Liu Z, Lin C, Mao X, Guo C, Suo C, Zhu D, Jiang W, Li Y, Fan J, Song C, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 2023;72(12):2354\u201363.","journal-title":"Gut"},{"issue":"6","key":"13925_CR30","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1007\/s11096-023-01608-7","volume":"45","author":"DC Moore","year":"2023","unstructured":"Moore DC, Elmes JB, Arnall JR, Strassels SA, Patel JN. Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis. Int J Clin Pharm. 2023;45(6):1492\u20135.","journal-title":"Int J Clin Pharm"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13925-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T06:23:38Z","timestamp":1746599018000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13925-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13925"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13925-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study and amendments were reviewed by an independent ethics committee or institutional review board at each study site: Ethics Committee of Peking University People\u2019s Hospital (#2020PHB401-01); Ethics Committee on Biomedical Research, West China Hospital of Sichuan University (#2021-EC-122); Medical Ethics Committee of Qilu Hospital, Shandong University (#(Ke)-EC-2020044); Medical Ethics Committee of Henan Provincial Cancer Hospital (#2020-289-001); Medical Ethics Committee of Tianjin Cancer Hospital (#E20210167); Human Research Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (#2021-EC-2023); Ethics Committee of Shengjing Hospital, China Medical University (#2021PS008T); Ethics Committee of Beijing Hospital (#2021BJYYEC-093-02); Ethics Committee of Anhui Provincial Cancer Hospital (#EC-2021-10); Ethics Committee of Henan Provincial People\u2019s Hospital (#2021-105-02); Ethics Committee of the Affiliated Hospital of Nantong University (#2021-K086-01); Ethics Committee of Tianjin Medical University General Hospital (#IRB2021-058-01); Ethics Committee of Qingdao Municipal Hospital (#2021-EC-017). The study and amendments were conducted in accordance with the principles of the Declaration of Helsinki and consistent with Good Clinical Practice guidelines and applicable regulatory requirements. All patients provided written informed consent prior to study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yanhui Li, Jianmin Zhuo, Xi Chen, and Canchan Cui are employees of Johnson & Johnson. Yishen Yang is an employee of IQVIA, which was contracted by Johnson & Johnson for the presented analyses. Jin Lu has served as a consultant and participated in the speakers bureau for Johnson & Johnson. The remaining authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"836"}}